Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT01216020 Terminated - Clinical trials for Head and Neck Neoplasms

Cetuximab Plus Radiotherapy Versus Cisplatin Plus Radiotherapy in Locally Advanced Head and Neck Cancer

CTXMAB+RT
Start date: October 2010
Phase: Phase 2
Study type: Interventional

BACKGROUND: Concomitant radiotherapy and cisplatin (CDDP) based chemotherapy is the standard treatment for LA-NHSCC. This combined modality treatment is linked with considerable acute local and systemic toxicity.EGFR is overexpressed in 90-100% of the HNSCC cases and is considered an unfavourable prognostic marker. EGFR costitutive activation is linked with HNSCC pathogenesis. Cetuximab is a monoclonal anti-EGFR antibody blocking the activation of the receptor and signal transduction. Cetuximab combined with radiotherapy is superior to radiotherapy only in the treatment of LA-HNSCC and is characterized by an acceptable toxicity profile. RATIONALE: A direct comparison between concomitant chemoradiotherapy with Cisplatin and the concomitant treatment with radiotherapy associated to cetuximab does not exist. STUDY DESIGN: Arm A: Radical radiotherapy (doses and volumes) concomitant with chemotherapy with Cisplatin (40 mg/mq/week) Arm B: Radical radiotherapy (doses and volumes) concomitant with therapy with the monoclonal antibody Cetuximab (400 mg/m2 ["loading dose"] and subsequently 250 mg /m2/week)

NCT ID: NCT01214642 Completed - Advanced Cancer Clinical Trials

A Dose-Escalation Study for Patients With Advanced Cancer

Start date: May 2008
Phase: Phase 1
Study type: Interventional

This study is being conducted to determine the safety of LY2523355 for the treatment of advanced and/or metastatic cancer (including Non-Hodgkin's lymphoma).

NCT ID: NCT01214629 Completed - Metastatic Cancer Clinical Trials

A Study for Participants With Advanced Cancer

Start date: July 2007
Phase: Phase 1
Study type: Interventional

This study is being conducted to determine the safety of LY2523355 for the treatment of advanced and/or metastatic cancer (including Non-Hodgkin's lymphoma).

NCT ID: NCT01214616 Completed - Neoplasms Clinical Trials

BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid Tumours

Start date: October 2010
Phase: Phase 1
Study type: Interventional

- To identify the Maximum Tolerated Dose (MTD) of afatinib in combination with vinorelbine i.v. by assessment of Dose Limiting Toxicities (DLT); - To assess safety and anti-tumour efficacy and determine pharmacokinetic characteristics of afatinib and vinorelbine i.v.

NCT ID: NCT01214343 Recruiting - Neoplasms Clinical Trials

Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC

Start date: October 2010
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of sorafenib in combination with low dose cisplatin /fluorouracil hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma.

NCT ID: NCT01213979 Completed - Clinical trials for Non-hematological Malignancies

Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia (CIA)

PK-CIA-04
Start date: February 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the pharmakokinetic properties of higher doses (500 mg and 1000 mg) of Monofer(R)in patients suffering from non-hematological malignancies with Chemotherapy induced anaemia.

NCT ID: NCT01213160 Completed - Cancer Clinical Trials

Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient

Start date: November 2010
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to explore the safety and tolerability of AZD4547 in Japanese patients with advanced solid malignancies.

NCT ID: NCT01212731 Completed - Glioma Clinical Trials

Skull Base and Low Grade Glioma Neurocognitive Magnetic Resonance Imaging (MRI) Study

Start date: September 2010
Phase:
Study type: Observational

The purpose of this study is to: - estimate the degree of memory loss, if any following radiotherapy to the base of skull or brain as measured by standard neurocognitive battery testing. - describe radiotherapy dose-related changes in vascular perfusion, in spectroscopic parameters of neuronal injury and changes in the degree and directionality of tissue water diffusivity (diffusion tensor imaging) as a measure of white axonal injury. - to relate these imaging characteristics to the degree of memory loss.

NCT ID: NCT01212107 Completed - Advanced Cancer Clinical Trials

A Phase 1 Study of LY2874455 in Participants With Advanced Cancer

Start date: December 2010
Phase: Phase 1
Study type: Interventional

The study is to determine the recommended Phase 2 regimen of study drug that may be safely administered to participants with advanced and or metastatic cancer. The study consists of two parts: a dose escalation and a dose confirmation.

NCT ID: NCT01207492 Active, not recruiting - Clinical trials for Tenosynovial Giant Cell Tumor

Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor

Start date: September 2010
Phase: Phase 2
Study type: Interventional

Nilotinib is a drug that is used to treat a form of a blood cancer called leukemia. Nilotinib works by blocking the action of a protein that might be important for the growth of pigmented villonodular synovitis (PVNS). In this research study the investigators are testing whether nilotinib can stop the growth of PVNS or improve the symptoms experienced from PVNS.